You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Colorcon
Johnson and Johnson
AstraZeneca
Dow

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MYCOBUTIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Mycobutin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002343 A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS Completed Pharmacia Phase 4 1969-12-31 To optimize Mycobacterium avium Complex (MAC) prophylaxis in AIDS patients by measuring serum rifabutin levels and adjusting the dose accordingly. To combine rifabutin with ethambutol to examine the effect of combination therapy in preventing or delaying the incidence of MAC bacteremia in this patient population.
NCT00598897 Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease Unknown status Abbott Phase 4 1995-08-01 To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
NCT00598897 Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease Unknown status Pfizer Phase 4 1995-08-01 To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
NCT00598897 Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease Unknown status The University of Texas Health Science Center at Tyler Phase 4 1995-08-01 To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
NCT00598962 Use of Azithromycin and Rifabutin Administered Three Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease Unknown status Pfizer Phase 4 1994-12-01 To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex
NCT00598962 Use of Azithromycin and Rifabutin Administered Three Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease Unknown status The University of Texas Health Science Center at Tyler Phase 4 1994-12-01 To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex
NCT00810407 Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients Completed Pfizer N/A 2008-11-01 The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mycobutin

Condition Name

Condition Name for Mycobutin
Intervention Trials
Tuberculosis 2
HIV Infections 2
Non-tuberculous Mycobacterial Diseases (Including MAC Disease) 2
Chlamydophila Pneumoniae Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mycobutin
Intervention Trials
Mycobacterium Infections 5
Mycobacterium avium-intracellulare Infection 4
HIV Infections 4
Infection 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mycobutin

Trials by Country

Trials by Country for Mycobutin
Location Trials
United States 3
Italy 1
Australia 1
South Africa 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mycobutin
Location Trials
Texas 2
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mycobutin

Clinical Trial Phase

Clinical Trial Phase for Mycobutin
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mycobutin
Clinical Trial Phase Trials
Completed 4
Unknown status 3
Recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mycobutin

Sponsor Name

Sponsor Name for Mycobutin
Sponsor Trials
Pfizer 4
Boehringer Ingelheim 2
The University of Texas Health Science Center at Tyler 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mycobutin
Sponsor Trials
Industry 8
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Harvard Business School
Dow
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.